subscales, physical component summary (PCS), mental component summary (MCS)]. We analyzed multivariable linear regression model to evaluate the association between obesity and HRQOL. RESULTS: Mean baseline age was 53.8 6 12.2 years and 61.6% were male. The prevalence of comorbidity included diabetes in 33.0%, hypertension in 96.0%, and cardiovascular disease in 11.0%. Mean BMI was 24.8 6 3.2 and 24.0 6 3.7 kg/m 2 for men and women, respectively, mean WC was 89.8 6 8.6 cm and 83.3 6 10.1 cm for men and women, respectively. In the multivariable linear regression models adjusted for age, sex, socioeconomic state, comobidities, smoking, physical activity, eGFR, hemoglobin, and albumin, BMI was not associated with PCS (b¼-0.07; 95% CI, -0.32 to 0.18) and MCS (b¼0.26; 95% CI, -0.01 to 0.52). WC was associated with PCS (b¼-0.11; 95% CI -0.20 to -0.02), but not MCS (b¼0.03; 95% CI, -0.06 to 0.13). WC was also significantly associated with PCS even after adjustment for BMI (b¼-0.25; 95% CI, -0.40 to -0.10). In the multivariate linear regression models for HRQOL in relation to GO and AO, AO was associated with poor physical HRQOL (b¼-2.24; 95% CI, -4.31 to -0.17). CONCLUSIONS: Our results suggest that abdominal obesity is associated with poorer physical HRQOL in adults with CKD, but general obesity is not associated with physical HROOL.
INTRODUCTION AND AIMS:
Renal cell carcinoma (CRC) is the 9th most common cancer in the world and its preferential treatment is partial nephrectomy (PN) in order to preserve more renal tissue and, consequently, its function. The amount of renal function preserved using this surgical method is still not well established and there may be the development of chronic kidney disease (CKD) even with PN. Aims: to evaluate the renal function of patients submitted to PN for localized renal tumors; to analyze the risk factors for progression of CKD in the postoperative period (PO) of PN. METHODS: A retrospective cohort study was carried out in which 85 patients underwent PN from 2009 to 2014, with name, age, gender, body mass index (BMI), type of surgical approach, type of tumor, associated morbidities, smoking habits and alcoholism, serum creatinine, and the glomerular filtration rate (eGFR) was evaluated in the preoperative period and in the 3rd month of the PO. The data were described in absolute and relative frequencies. Outcomes were described by the Pearson method. To verify differences in frequency of outcomes, Pearson's Chi-square test or Fisher's exact test was used. For the characteristics associated with the outcome, the odds ratios and their confidence intervals were calculated. The results were considered significant when p <0.05. RESULTS: previous diagnosis of CKD was observed in 41.2% of the patients. There was a significant increase in creatinine values and a significant reduction of eGFR in the 3rd PO month. 13 new cases of CKD were found in the 3rd PO period, while 17.1% of the patients progressed in the disease. The presence of perirenal adipose tissue, structural invasion, tissue changes, bleeding and the need for ICUs in the 3rd month of the OP were directly proportional to the progression of CKD. CONCLUSIONS: there was progression of the stage in patients who had previous CKD to PN. PN also caused new cases of CKD. Neoplastic invasion in perirenal adipose tissue and tissue-specific changes in peri-tumor tissue have shown significant associations with the combined outcome of CKD progression. 
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INTRODUCTION AND AIMS:
Inflammation is a common feature in chronic kidney disease (CKD), particularly enhanced in end stage renal disease (ESRD) patients on hemodialysis (HD). The chronic inflammatory state contributes to the raise of inflammatory biomarkers such as C-reactive protein (CRP) and pro-inflammatory cytokines. ESRD patients present different types of DNA injury and increased levels of circulating cell-free DNA (cfDNA). The positive correlation between the levels of DNA damage and the mortality risk in CKD patients suggests that genomic damage can be valuable for prognosis in these patients. The aim of this work was to evaluate the degree of genomic damage in ESRD patients on HD, using the comet assay and the cfDNA, to assess DNA damage within the cell and the circulating free DNA. We studied also the association between DNA damage and death occurring in one-year follow-up period. METHODS: We evaluated the degree of genomic injury in 37 ESRD patients under HD therapy, for more than 1 year, and in 15 healthy controls, using the alkaline in vitro comet assay and the cfDNA quantification; and sociodemographic data, hematologic and inflammatory markers. RESULTS: We found that ESRD patients presented significantly higher CRP values and cell damaged DNA, compared to controls. The cfDNA values were correlated with age and inflammatory state. Twenty-two percent of the patients died during one year follow-up period and presented significantly higher values of cfDNA, CRP and age, and lower iron levels, than those who persisted alive (n¼29). CONCLUSIONS: Our findings showed that DNA damaged increased in ESRD patients, and suggest that at lower CRP values this damage still remains within the cell, while at higher CRP values DNA is released into plasma and may contribute to further enhance inflammation and increase mortality risk. The cfDNA values and higher degree of DNA damage, correlated with age and inflammatory state, may contribute to raise the risk of cancer and cardiovascular events. Moreover, our data suggest that the comet assay is more sensitive for low-grade inflammatory conditions, while cfDNA appears as a good biomarker for more severe inflammatory conditions and for the outcome of ESRD patients. Those who died sooner presented enhanced DNA damage in circulation and inflammation, suggesting that cfDNA and CRP can be used as biomarkers of poor outcome in ESRD patients.WORK AGREEMENT: The presenting author and all coauthors agree with the submission and content of this INTRODUCTION AND AIMS: Cardiovascular calcification (CVC) is a major contributor to the high incidence of cardiovascular events (CVE) in chronic kidney disease (CKD). Early CVC markers are actively sought now in CKD for cardio-renoprotective strategy optimization. Few studies examined novel CKD specific factors in parallel. No data are available from Russian CKD patients. We have conducted a cross-sectional study of FGF-23 (sFGF-23), Klotho (sKlotho) and sclerostin (sScl) serum levels along with traditional CKD-related factors such as serum phosphate (sP) and parathyroid hormone (PTH) and some general factors such as blood pressure, and examined their independent association with CVC in CKD patients. METHODS: 131 CKD stage 1-5D patients were examined. In addition to routine laboratory tests, sFGF-23 (human FGF-23 ELISA (Merck Millipore) kit using monoclonal antibodies to the native human FGF-23 molecule), sKlotho (human soluble alfaKlotho Assay (IBL-Takara), sScl (human ELISA kit , Biomedica) were measured. Pulse wave velocity (PWV) and central (aortic) blood pressure (by «Sphygmocor», Australia), cardiac (valvular) calcification score (by Echocardiography, semiquantitative scale), and aortic calcinosis score (by abdominal aorta radiography in lateral projection -Kauppila method) were performed. RESULTS: In univariate analysis, all the factors of interest (sFGF-23, sKlotho, sScl) and also traditional CKD-related factors (sP, PTH and eGFR itself) as well as general factors (CSBP) were associated with PWV, aortic and valvular calcification. After multivariate analysis, including eGFR, was performed, sKlotho, sFGF-23, sP and CSBP results remained unchanged. The effects of sScl were lost except for the PWV, and the effects of eGFR were lost except for the presence of vascular calcification. PTH was associated only with valvular calcification. After subdividing the cohort by eGFR above or below 45 ml/min/1.73m2 the factors most associated with CVC in the former were: CSBP and sKlotho, while in the latter subgroup these main factors were: CSBP, sKlotho, FGF-23 and sP. CONCLUSIONS: In early CKD stages (eGFR> 45 ml/min/1.73m2), the main independent factors associated with CVC were not only the same for general population such as CSBP, but also sKlotho, while for the subgroup with eGFR<45 ml/min/1.73m2, these main CVC factors were: CSBP, sKlotho, FGF-23 and sP. (FGF23) is secreted by osteoblasts and osteocytes and mainly regulates phosphate homeostasis and calcitriol levels. The bioactive intact FGF23 contains 251 amino acids and is glycosylated and phosphorylated. Its activity is mediated by binding to FGFR/Klotho receptor complex at the target cell surface. Intact FGF23 is cleaved between Arg179 and Ser180 to an Nterminal and a C-terminal fragment. Several studies revealed that FGF23 concentrations are increased in chronic kidney disease, oncogenic osteomalacia and several rare hereditary disorders. Most of these measurements were performed by using immunoassays, which detect only intact (intact FGF23 ELISA) or both intact and C-terminal fragments (C-terminal FGF23 ELISA). METHODS: Here, we show the validation and characterization of a C-terminal multimatrix FGF23 ELISA. Epitopes of both polyclonal antibodies were analyzed by overlapping linear peptides spotted to a microarray and also determination of binding kinetics with biolayer interferometry was performed. The assay was validated according to standard quality guidelines with a special focus on matrix comparison (serum and EDTA, heparin and citrate plasma) and analyte stability. RESULTS: Linear epitopes of both polyclonal antibodies are distributed throughout the C-terminal part of FGF23 and antibodies bind with high affinity to FGF23. The assay generates highly specific FGF23 signals (>90%), a mean accuracy and dilution linearity of 85-110% and 90-108%, respectively. Both, intra-as well as inter-assay precision are within the standard of acceptance. Compared with other C-terminal FGF23 ELISA on the market, that detect FGF23 only in plasma, this C-terminal assay can be used for the measurement of serum as well as. Matrix comparison of serum and plasma of apparently healthy and dialysis patients show a good correlation with R 2 > 0.85. Endogenous FGF23 is freeze-thaw stable in serum and plasma for at least 4 cycles, whereas whole blood stability is better for plasma than for serum samples. CONCLUSIONS: This well-characterized and fully validated C-terminal FGF23 ELISA can be used for the measurement of human serum and plasma samples and may support further FGF23 research.
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